Compare Cytokinetics Inc (CYTK) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Essex Property Trust, Inc. — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Essex Property Trust, Inc. trades at $269.13 (market cap $17.23B). The key difference: Essex Property Trust, Inc. is far larger — about 2× Cytokinetics Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Essex Property Trust, Inc. for 111 Days on average.
| CYTK | ESS | |
|---|---|---|
Market Cap | $8.50B | $17.23B |
Volume | 2,395,556 | 346,109 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $298.33 |
52-Week Low | $54.76 | $239.61 |
Typical Hold Time | 19 Days | 111 Days |
Enterprise Value | $8.60B | $23.82B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
ESS trades at $268.05, down 1.63% with bearish technical signals. The company reported mixed Q2 2026 results, beating FFO estimates but missing EPS expectations. Strong operational performance and litigation resolution provide fundamental support, though high valuation ratios and debt levels present concerns. Recent institutional buying and a $2.59 dividend declaration highlight investor confidence.
Outlook remains cautiously optimistic with a $303.41 consensus price target offering 13% upside. Key risks include earnings volatility, high leverage, and regional economic exposure. The stock presents a balanced opportunity for income-focused investors seeking quality REIT exposure with disciplined risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
